ESTRO 2024 - Abstract Book

S1071

Clinical - Gynaecology

ESTRO 2024

Keywords: reirradiation, gynaecology, brachytherapy, SBRT

2293

Proffered Paper

Acute gastrointestinal toxicity of concurrent chemoradiation in cervix cancer: EMBRACE-II findings

Mayuri S Charnalia 1 , Kari Tanderup 1,2 , Richard Pötter 3 , Supriya Chopra 4 , Marta Pelizzola 1 , Ina M Jurgenliemk Schulz 5 , Maximilian P Schmid 3 , Kjersti Bruheim 6 , Barbara Segedin 7,8 , Henrike G Westerveld 9,10 , Ericka Wiebe 11 , Margit Valgma 12 , Laura A Velema 13 , Lia C.G. Verhoef 14 , Li Tee Tan 15 , Jacob C Lindegaard 16 , Rachel Cooper 17 , Hanne F Mathiesen 18 , Christian Kirisits 3 , Monica Serban 19 , Jeevanshu Jain 4 , Kathrin Kirchheiner 3 , Remi A Nout 10 , Sofia Spampinato 1 1 Aarhus University Hospital, Danish Centre for Particle Therapy, Aarhus, Denmark. 2 Aarhus University, Department of Clinical Medicine, Aarhus, Denmark. 3 Comprehensive Cancer Center, Medical University of Vienna, Department of Radiation Oncology, Vienna, Austria. 4 Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Department of Radiation Oncology, Navi Mumbai, India. 5 University Medical Centre Utrecht, Department of Radiation Oncology, Utrech, Netherlands. 6 Oslo University Hospital, Department of Oncology, Oslo, Norway. 7 Institute of Oncology, Department of Radiotherapy, Ljubljana, Slovenia. 8 Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. 9 Academic Medical Centre, University of Amsterdam, Department of Radiotherapy, Amsterdam, Netherlands. 10 Erasmus MC Cancer Institute, Department of Radiotherapy, Rotterdam, Netherlands. 11 Cross Cancer Institute, University of Alberta, Department of Oncology, Edmonton, Canada. 12 North Estonia Medical Centre Foundation, Radiotherapy Centre, Tallinn, Estonia. 13 Leiden University Medical Center, Department of Radiation Oncology, Leiden, Netherlands. 14 Radboud University Medical Center and Radboud Institute for Health Sciences, Department of Radiotherapy, Nijmegen, Netherlands. 15 Cambridge University Hospitals NHS Foundation Trust, Oncology Centre, Cambridge, United Kingdom. 16 Aarhus University Hospital, Department of Oncology, Aarhus, Denmark. 17 St James's Institute of Oncology, Leeds Cancer Centre, Leeds, United Kingdom. 18 Rigshospitalet, Department of Oncology, Copenhagen, Denmark. 19 Princess Margaret Cancer Centre, Radiation Medicine Program, Toronto, Canada

Purpose/Objective:

To evaluate the incidence of acute gastrointestinal (GI) toxicity and the association with external beam radiotherapy (EBRT) elective target volume selection and nodal boosting in locally advanced cervical cancer (LACC) patients enrolled in EMBRACE-II.

Material/Methods:

EMBRACE-II is an international prospective study (enrolment period 2016-2021). Patients received intensity modulated radiotherapy or volumetric arc therapy and chemotherapy followed by MRI-guided brachytherapy. EBRT was delivered with highly conformal dose distributions including coverage probability planning [1] for simultaneously integrated nodal boosts. EBRT elective target prescription dose was 45Gy in 25 fractions. Dose prescription to positive pelvic and para-aortic nodes was according to institutional practice with recommendation that overall contribution should preferably be between 55Gy and 65Gy equivalent dose in 2Gy per fraction. GI toxicity (CTCAEv3.0) was recorded at baseline (BM), four weeks after start of treatment (RT4W), end of treatment (RTEND), and regular follow-ups from 3 months (3M) and onwards. This analysis included assessments at BM,